Investing.com - Calidi Biotherapeutics (NYSE: CLDI) reported fourth quarter EPS of $-0.23, $0.03 worse than the analyst estimate of $-0.20. Revenue for the quarter came in at $0.00 versus the consensus estimate of $0.00.
Calidi Biotherapeutics's stock price closed at $0.62. It is down -65.56% in the last 3 months and down -93.96% in the last 12 months.
Calidi Biotherapeutics saw positive EPS revisions and negative EPS revisions in the last 90 days. See Calidi Biotherapeutics's stock price’s past reactions to earnings here.
According to InvestingPro, Calidi Biotherapeutics's Financial Health score is "weak performance".
Check out Calidi Biotherapeutics's recent earnings performance, and Calidi Biotherapeutics's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar